InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $2.280 0.01 (0.44%)+

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$851 Notification regarding unquoted securities - CU6 27 May 2026 4:41PM $2.610 $2.280 fallen by 12.64%
$851 Cleansing Notice 20 May 2026 4:57PM $2.520 $2.280 fallen by 9.52%
$851 Application for quotation of securities - CU6 20 May 2026 4:54PM $2.520 $2.280 fallen by 9.52%
$851 Clarity receives $9.8 million R&D tax incentive refund 14 May 2026 9:43AM $2.850 $2.280 fallen by 20%
$851 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2026 12:24PM $2.935 $2.280 fallen by 22.32%
$851 Change of Director's Interest Notice - Parker 22 Apr 2026 4:23PM $2.930 $2.280 fallen by 22.18%
$851 Clarity signs a Commercial Manufacturing Agreement 14 Apr 2026 8:33AM $3.130 $2.280 fallen by 27.16%
$851 Ceasing to be a substantial holder 10 Apr 2026 5:01PM $3.180 $2.280 fallen by 28.30%
$851 Becoming a substantial holder 9 Apr 2026 4:12PM $3.140 $2.280 fallen by 27.39%
$851 Final Director's Interest Notice - Biggin 9 Apr 2026 9:42AM $3.250 $2.280 fallen by 29.85%
$851 Director Appointment/Resignation 9 Apr 2026 8:57AM $3.250 $2.280 fallen by 29.85%
$851 Notification regarding unquoted securities - CU6 7 Apr 2026 11:22AM $3.180 $2.280 fallen by 28.30%
$851 Cleansing Notice 31 Mar 2026 5:15PM $3.100 $2.280 fallen by 26.45%
$851 Application for quotation of securities - CU6 31 Mar 2026 5:11PM $3.100 $2.280 fallen by 26.45%
$851 Co-PSMA data published in the European Urology journal 31 Mar 2026 9:20AM $3.030 $2.280 fallen by 24.75%
$851 Becoming a substantial holder 26 Mar 2026 8:16AM $3.440 $2.280 fallen by 33.72%
$851 Clarity signs a large-scale Manufacturing Supply Agreement 25 Mar 2026 9:24AM $3.070 $2.280 fallen by 25.73%
$851 Co-PSMA data presented 17 Mar 2026 9:40AM $3.620 $2.280 fallen by 37.02%
$851 Cleansing Notice 11 Mar 2026 12:34PM $3.820 $2.280 fallen by 40.31%
$851 Application for quotation of securities - CU6 11 Mar 2026 12:28PM $3.800 $2.280 fallen by 40%
$851 AMPLIFY trial - Target number of participants achieved 10 Mar 2026 9:03AM $3.290 $2.280 fallen by 30.70%
$851 Notification regarding unquoted securities - CU6 2 Mar 2026 11:41AM $3.350 $2.280 fallen by 31.94%
$851 Half Year Accounts 27 Feb 2026 9:51AM $3.600 $2.280 fallen by 36.67%
$851 Half Yearly Report and Accounts 27 Feb 2026 9:48AM $3.600 $2.280 fallen by 36.67%
$851 SECuRE trial update 23 Feb 2026 9:00AM $3.510 $2.280 fallen by 35.04%

26 - 50 of 511 results

Page 2 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.